Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Non-Current Deffered Revenue (2016 - 2025)

Traws Pharma (TRAW) has disclosed Non-Current Deffered Revenue for 14 consecutive years, with $2.5 million as the latest value for Q1 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 8.3% to $2.5 million in Q1 2025 year-over-year; TTM through Mar 2025 was $2.5 million, a 8.3% decrease, with the full-year FY2024 number at $2.6 million, down 8.1% from a year prior.
  • Non-Current Deffered Revenue was $2.5 million for Q1 2025 at Traws Pharma, down from $2.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $3.4 million in Q1 2021 to a low of $2.5 million in Q1 2025.
  • A 5-year average of $3.0 million and a median of $3.0 million in 2023 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: dropped 6.21% in 2021, then fell 8.3% in 2025.
  • Traws Pharma's Non-Current Deffered Revenue stood at $3.2 million in 2021, then decreased by 6.97% to $3.0 million in 2022, then decreased by 7.49% to $2.8 million in 2023, then fell by 8.1% to $2.6 million in 2024, then decreased by 2.22% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Non-Current Deffered Revenue are $2.5 million (Q1 2025), $2.6 million (Q4 2024), and $2.6 million (Q3 2024).